Extensive intestinal first-pass metabolism of arctigenin: Evidenced by simultaneous monitoring of both parent drug and its major metabolites

Journal of Pharmaceutical and Biomedical Analysis

Volumn 91, Issue , 2014, Pages 60-67

  Gao, Qiong ^a   Zhang, Yufeng ^a   Wo, Siukwan ^a   Zuo, Zhong ^a  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

Arctigenic acid; Arctigenin; Arctigenin 4' O glucuronide; Intestinal first pass metabolism; UPLC MS MS

Indexed keywords

ACETONITRILE; ANTINEOPLASTIC AGENT; ARCTIGENIC ACID; ARCTIGENIN; ARCTIGENIN 4' O GLUCURONIDE; DRUG METABOLITE; FORMIC ACID; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ARTICLE; CELL STRAIN CACO 2; CHROMATOGRAPHY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG MONITORING; DRUG PENETRATION; ENZYME METABOLISM; FIRST PASS EFFECT; HUMAN; HUMAN CELL; INTESTINE ABSORPTION; INTESTINE PERFUSION; LIMIT OF QUANTITATION; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL; RAT; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

ARCTIGENIC ACID; ARCTIGENIN; ARCTIGENIN-4′-O-GLUCURONIDE; INTESTINAL FIRST-PASS METABOLISM; UPLC/MS/MS;

ANIMALS; CACO-2 CELLS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FURANS; HUMANS; INTESTINAL ABSORPTION; INTESTINES; LIGNANS; MALE; PERMEABILITY; PLASMA; RATS; RATS, SPRAGUE-DAWLEY; TANDEM MASS SPECTROMETRY;

EID: 84892469207     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2013.12.017     Document Type: Article

References (43)

1. Dombradi G.A. Tumour-growth inhibiting substances of plant origin. 2. Experimental animal tumour-pharmacology of arctigenin-mustard. Chemotherapy 1970, 15:250-265.
2. Awale S., Lu J., Kalauni S.K., Kurashima Y., Tezuka Y., Kadota S., Esumi H. Identification of arctigenin as an antitumor agent having the ability to eliminate the tolerance of cancer cells to nutrient starvation. Cancer Res. 2006, 66:1751-1757.
3. Wang L., Zhao F., Liu K. Induction of apoptosis of the human leukemia cells by arctigenin and its mechanism of action. Chin. J. Chem. 2008, 43:542-547.
4. Gu Y., Scheuer C., Feng D., Menger M.D., Laschke M.W. Inhibition of angiogenesis: a novel antitumor mechanism of the herbal compound arctigenin. Anticancer Drugs 2013, 24:781-791.
5. Shoeb M., Celik S., Jaspars M., Kumarasamy Y., MacManus S.M., Nahar L., Paul K.T.L.D., Sarker S.D. Isolation, structure elucidation and bioactivity of schischkiniin, a unique indole alkaloid from the seeds of Centaurea schischkinii. Tetrahedron 2005, 61:9001-9006.
6. Kang K., Lee H.J., Kim C.Y., Lee S.B., Tunsag J., Batsuren D., Nho C.W. The chemopreventive effects of Saussurea salicifolia through induction of apoptosis and phase II detoxification enzyme. Biol. Pharm. Bull. 2007, 30:2352-2359.
7. Strimpakos A.S., Saif M.W. Update on phase I studies in advanced pancreatic adenocarcinoma. Hunting in darkness?. JOP 2013, 14:354-358.
8. Hayashi K., Narutaki K., Nagaoka Y., Hayashi T., Uesato S. Therapeutic effect of arctiin and arctigenin in immunocompetent and immunocompromised mice infected with influenza A virus. Biol. Pharm. Bull. 2010, 33:1199-1205.
9. Yang Z., Liu N., Huang B., Wang Y., Hu Y., Zhu Y. Effect of anti-influenza virus of arctigenin in vivo. Zhongyaocai 2005, 28:1012-1014.
10. Kim Y., Hollenbaugh J.A., Kim D.H., Kim B. Novel PI3K/Akt inhibitors screened by the cytoprotective function of human immunodeficiency virus type 1 Tat. PLoS ONE 2011, 6:e21781.
11. Hyam S.R., Lee I.A., Gu W., Kim K.A., Jeong J.J., Jang S.E., Han M.J., Kim D.H. Arctigenin ameliorates inflammation in vitro and in vivo by inhibiting the PI3K/AKT pathway and polarizing M1 macrophages to M2-like macrophages. Eur. J. Pharmacol. 2013, 708:21-29.
12. Tsai W.J., Chang C.T., Wang G.J., Lee T.H., Chang S.F., Lu S.C., Kuo Y.C. Arctigenin from Arctium lappa inhibits interleukin-2 and interferon gene expression in primary human T lymphocytes. Chin. Med. 2011, 6:12.
13. Kou X.J., Qi S.M., Dai W.X., Luo L., Yin Z.M. Arctigenin inhibits lipopolysaccharide-induced iNOS expression in RAW264.7 cells through suppressing JAK-STAT signal pathway. Int. Immunopharmacol. 2011, 11:1095-1102.
14. Zhu Z., Yan J., Jiang W., Yao X.G., Chen J., Chen L., Li C., Hu L., Jiang H., Shen X. Arctigenin effectively ameliorates memory impairment in Alzheimer's disease model mice targeting both beta-amyloid production and clearance. J. Neurosci. 2013, 33:13138-13149.
15. Kasper R., Gansser D., Doehmer J. Biotransformation of the naturally-occurring lignan (-)-arctigenin in mammalian-cell lines genetically-engineered for expression of single cytochrome-P450 isoforms. Planta Med. 1994, 60:441-444.
16. Zhao Y.F., Song F.R., Zhao L.P., Liu S.Y. Studies on the biotransformation of arctigenin using electrospray ionization mass spectrometry. Chin. J. Chem. 2009, 67:1123-1126.
17. Heinonen S., Nurmi T., Liukkonen K., Poutanen K., Wahala K., Deyama T., Nishibe S., Adlercreutz H. In vitro metabolism of plant lignans: new precursors of mammalian lignans enterolactone and enterodiol. J. Agric. Food Chem. 2001, 49:3178-3186.
18. Zhao D., Zhang Y., Xu C., Dong C., Lin H., Zhang L., Li C., Ren S., Wang X., Yang S., Han D., Chen X. Pharmacokinetics, tissue distribution, and plasma protein binding study of platinum originating from dicycloplatin, a novel antitumor supramolecule, in rats and dogs by ICP-MS. Biol. Trace Elem. Res. 2012, 148:203-208.
19. He F., Dou D.Q., Hou Q., Sun Y., Kang T.G. Pharmacokinetic study of arctigenin in rat plasma and organ tissue by RP-HPLC method. Nat. Prod. Res. 2013, 27:903-906.
20. Zou Q., Gu Y., Lu R., Zhang T., Zhao G.R., Liu C., Si D. Development of an LC/MS/MS method in order to determine arctigenin in rat plasma: its application to a pharmacokinetic study. Biomed. Chromatogr. 2013, 27:1123-1128.
21. Gao Q., Zhang Y., Wo S., Zuo Z. Hydrolysis is the dominating in vivo metabolism pathway for arctigenin: identification of novel metabolites of arctigenin by LC/MS/MS after oral administration in rats. Planta Med. 2013, 79:471-479.
22. Wong Y.C., Zhang L., Lin G., Zuo Z. Intestinal first-pass glucuronidation activities of selected dihydroxyflavones. Int. J. Pharm. 2009, 366:14-20.
23. Guidance for Industry: Bioanalytical Method Validation 2001, US Food and Drug Administration, Center for Drug Evaluation and Research.
24. Bonfiglio R., King R.C., Olah T.V., Merkle K. The effects of sample preparation methods on the variability of the electrospray ionization response for model drug compounds. Rapid Commun. Mass Spectrom. 1999, 13:1175-1185.
25. Rocci M.L., Devanarayan V., Haughey D.B., Jardieu P. Confirmatory reanalysis of incurred bioanalytical samples. AAPS J. 2007, 9:E336-E343.
26. Zhang L., Lin G., Chang Q., Zuo Z. Role of intestinal first-pass metabolism of baicalein in its absorption process. Pharm. Res. 2005, 22:1050-1058.
27. Zhou L., Chow M.S., Zuo Z. Effect of sodium caprate on the oral absorptions of danshensu and salvianolic acid B. Int. J. Pharm. 2009, 379:109-118.
28. Johnson B.M., Chen W., Borchardt R.T., Charman W.N., Porter C.J. A kinetic evaluation of the absorption, efflux, and metabolism of verapamil in the autoperfused rat jejunum. J. Pharmacol. Exp. Ther. 2003, 305:151-158.
29. Zheng Y.M., Cai S.X., Xu X.Y., Fu S.Q. Dyuamical studies on metabolic chemistry of lignans from seeds of Arctium lappa. Zhongguo Zhong Yao Za Zhi 2005, 30:1287-1289.
30. Kim M.J., Im K.R., Yoon K.S. Anti-inflammatory effects of YeongyoSeungma-tang. J. Ethnopharmacol. 2009, 126:377-381.
31. Wang W., Pan Q., Han X.Y., Wang J., Tan R.Q., He F., Dou D.Q., Kang T.G. Simultaneous determination of arctiin and its metabolites in rat urine and feces by HPLC. Fitoterapia 2013, 86:6-12.
32. Artursson P. Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. J. Pharm. Sci. 1990, 79:476-482.
33. Cogburn J.N., Donovan M.G., Schasteen C.S. A model of human small intestinal absorptive cells. 1. Transport barrier. Pharm. Res. 1991, 8:210-216.
34. Walgren R.A., Walle U.K., Walle T. Transport of quercetin and its glucosides across human intestinal epithelial Caco-2 cells. Biochem. Pharmacol. 1998, 55:1721-1727.
35. Sun D., Lennernas H., Welage L.S., Barnett J.L., Landowski C.P., Foster D., Fleisher D., Lee K.D., Amidon G.L. Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. Pharm. Res. 2002, 19:1400-1416.
36. Varma M.V., Kapoor N., Sarkar M., Panchagnula R. Simultaneous determination of digoxin and permeability markers in rat in situ intestinal perfusion samples by RP-HPLC. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2004, 813:347-352.
37. Mols R., Brouwers J., Schinkel A.H., Annaert P., Augustijns P. Intestinal perfusion with mesenteric blood sampling in wild-type and knockout mice: evaluation of a novel tool in biopharmaceutical drug profiling. Drug Metab. Dispos. 2009, 37:1334-1337.
38. Walle U.K., Galijatovic A., Walle T. Transport of the flavonoid chrysin and its conjugated metabolites by the human intestinal cell line Caco-2. Biochem. Pharmacol. 1999, 58:431-438.
39. Jia X., Chen J., Lin H., Hu M. Disposition of flavonoids via enteric recycling: enzyme-transporter coupling affects metabolism of biochanin A and formononetin and excretion of their phase II conjugates. J. Pharmacol. Exp. Ther. 2004, 310:1103-1113.
40. Petri N., Tannergren C., Holst B., Mellon F.A., Bao Y.P., Plumb G.W., Bacon J., O'Leary K.A., Kroon P.A., Knutson L., Forsell P., Eriksson T., Lennernas H., Williamson G. Absorption/metabolism of sulforaphane and quercetin, and regulation of phase II enzymes, in human jejunum in vivo. Drug Metab. Dispos. 2003, 31:805-813.
41. Jin J.S., Hattori M. Human intestinal bacterium, strain END-2 is responsible for demethylation as well as lactonization during plant lignan metabolism. Biol. Pharm. Bull. 2010, 33:1443-1447.
42. Jin J.S., Kakiuchi N., Hattori M. Enantioselective oxidation of enterodiol to enterolactone by human intestinal bacteria. Biol. Pharm. Bull. 2007, 30:2204-2206.
43. Jan K.C., Hwang L.S., Ho C.T. Biotransformation of sesaminol triglucoside to mammalian lignans by intestinal microbiota. J. Agric. Food Chem. 2009, 57:6101-6106.